Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Nextech3D.ai Announces First New Customer Win For its AI Powered Photography Studio (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. LMNL

Healthcare Biotechnology
Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Liminal BioSciences Inc. > just called them, they transfered me to a stephen
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(22)
•••
Comment by 4Justiceon Dec 11, 2019 12:23pm
196 Views
Post# 30444196

RE:RE:RE:just called them, they transfered me to a stephen

RE:RE:RE:just called them, they transfered me to a stephenLyne Gagnon, Vice-President R&D Pre-clinical Studies and with Prometic for 21 years and Senior Research Scientist with Biochem Pharma for 5 years and the leader of the 3TC discovery and behind our long list of promising PBI was laid off november 28th few minutes after the AMF CC.

Friday december the 6  6 high level reserchers, working with Lyne since long time were also laid off.

In other division more than 25 people have been laid off to.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities